Todd L. Cecil - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Todd L. Cecil


Todd L. Cecil
Vice-President,
Compendial Science,
United States Pharmacopeia

Todd L. Cecil, PhD, is the vice-president of compendial science at USP. He has been with the organization since 1993 and has held the following positions: director of noncomplex actives and general policies and requirements; project manager of new monograph development project; scientist; and chemist III.

Cecil is presently a member of the American Association of Pharmaceutical Scientists (AAPS) and ACS. While at AAPS, he has held the positions of secretary treasurer, vice-chair, chair-elect, chair, and past-chair of the APQ Section of AAPS; chair APQ Workshop Committee; and AAPS APQ lead paper screener. He is the author of seven publications and has made more than 60 national and international presentations.

He holds a BS in chemistry from the University of Iowa and a PhD in analytical chemistry from Virginia Commonwealth University.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here